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INTRODUCTION
Imagine a future where large corporations use CRISPR, a genetic
editing tool, to modify almost every living thing.1 Perfectly mani-
cured lawns are comprised of genetically-modified grasses, people
adore their genetically-modified pets, and parents select only the
best traits to be carried by their genetically-modified children.2 This
is a future T. Coraghassen Boyle recently imagined in a short story
in The New Yorker.3 In Boyle’s story, genetic editing is supposed to
lead to perfect happiness by removing all flaws from the natural
world.4 The only catch is that the new, genetically perfect world
feels wholly unnatural to some of the people living in it.5
The dystopian future envisioned in Boyle’s story is fast becoming
scientifically possible.6 (Whether it is ethically desirable is an
entirely separate matter.7) CRISPR-Cas9, short for “Clustered
Regularly Interspaced Short Palindromic Repeats” and “CRISPR-
associated protein 9” is a genetic-editing technology that allows
1. This scenario comes from T. Coraghessan Boyle, Are We Not Men?, NEW YORKER (Nov.
7, 2016), https://www.newyorker.com/magazine/2016/11/07/are-we-not-men [https://perma.cc/
ZJG5-UF9P].
2. Id.
3. Id.
4. Id. Boyle’s description of how genetic editing could change reproduction is illustrative:
What sort of child—that was the question. Previous generations had only to fret
over whether the expectant mother would bear a boy or a girl or if the child
would inherit Aunt Bethany’s nose or Uncle Yuri’s unibrow, but that wasn’t the
case anymore, not since CRISPR gene-editing technology had hit the ground
running twenty years back. Now not only could you choose the sex of the child
at conception; you could cho[o]se its other features, too, as if having a child were
like going to the car dealership and picking which options to add onto the basic
model. The sole function of sex these days was recreational; babies were
conceived in the laboratory.
Id.
5. Id.
6. See, e.g., Paul Enríquez, Genome Editing and the Jurisprudence of Scientific Empiri-
cism, 19 VAND. J. ENT. & TECH. L. 603 (2017) (providing—as he might put it—a sesquipedalian
overview of the science behind genome editing, geared towards a legal audience).
7. See, e.g., Rebecca Cokley, Please Don’t Edit Me Out, WASH. POST (Aug. 10, 2017),
https://www.washingtonpost.com/opinions/if-we-start-editing-genes-people-like-me-might-not-
exist/2017/08/10/e9adf206-7d27-11e7-a669-b400c5c7e1cc_story.html?utm_term=.22df9b9
f32Dd [https://perma.cc/CH3V-ARML] (arguing that using genetic editing technologies to
remove disabilities from the human genome is a short-sighted strategy that does not account
for the valuable contributions that disabled people make to society).
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scientists to edit DNA with a remarkable degree of accuracy.8 It is
an advance on other genetic-editing technologies, which had limited
programmability and, in turn, often caused off-target effects (edits
to segments of DNA that the researcher was not trying to impact).9
Scientists continuously find new, creative uses of CRISPR-Cas9,10
and the technology is increasingly in the public eye.11 The FDA
recently issued a press release warning consumers that the sale of
“do it yourself ” CRISPR kits is against the law due to safety con-
cerns about CRISPR-Cas9-mediated gene therapies.12 Chinese sci-
entists reported in October of 2016 that they had injected a lung
cancer patient with cells modified by CRISPR-Cas9,13 scientists at
Oregon Health & Science University reported in August of 2017
that they had made CRISPR-mediated repairs to non-viable human
8. See Taeyoung Koo & Jin-Soo Kim, Therapeutic Applications of CRISPR RNA-Guided
Genome Editing, 16 BRIEFINGS FUNCTIONAL GENOMICS 38, 38, 43 (2017).
9. Samuel H. Sternberg & Jennifer A. Doudna, Expanding the Biologist’s Toolkit with
CRISPR-Cas9, 58 MOLECULAR CELL 568, 569 (2015).
10. See, e.g., Heidi Ledford, Lights, Camera, CRISPR: Biologists Use Gene Editing to Store
Movies in DNA, NATURE (July 12, 2017), http://www.nature.com/news/lights-camera-crispr-
biologists-use-gene-editing-to-store-movies-in-dna-1.22288 [https://perma.cc/Q9YV-SBTB] (de-
scribing how scientists used CRISPR-Cas9 “to encode a movie into the genome of the [E. coli
bacteria]”).
11. A Google Alert return for “CRISPR Cas9” from October 10, 2017, is instructive. It
included, among many others, links to Steve Dent, Anti-Doping Agency to Ban Gene Editing
Starting in 2018, ENGADGET (Oct. 10, 2017), https://www.engadget.com/2017/10/10/wada-
banning-sports-gene-editing-doping/ [https://perma.cc/ZU9D-CR7B] (describing the World
Anti-Doping Agency’s plan to ban “gene editing agents designed to alter genome sequences”);
Gene Drives Have the Potential to Suppress Mosquito Populations, ECON. TIMES (Oct. 10, 2017,
10:35 AM), https://health.economictimes.indiatimes.com/news/industry/gene-drives-have-the-
potential-to-suppress-mosquito-populations/61016289 [https://perma.cc/PUG7-B797] (de-
scribing attempts by researchers to reduce fertility in female mosquitos using CRISPR
editing); Skakel McCooey, Yale Study Sheds New Light on Limb Regeneration, YALE DAILY
NEWS (Oct. 10, 2017), https://yaledailynews.com/blog/2017/10/10/yale-study-sheds-new-light-
on-limb-regeneration/ [https://perma.cc/A6FR-FE8Q] (describing a paper published by Yale
researchers who used CRISPR to study limb regeneration in salamanders).
12. Press Release, Food & Drug Admin., Information About Self-Administration of Gene
Therapy (Nov. 21, 2017) (available at https://www.fda.gov/BiologicsBloodVaccines/Cellular
GeneTherapyProducts/ucm586343.htm) [https://perma.cc/P7BV-RKAU].
13. See David Cyranoski, CRISPR Gene-Editing Tested in a Person for the First Time,
NATURE (Nov. 15, 2016), http://www.nature.com/news/crispr-gene-editing-tested-in-a-person-
for-the-first-time-1.20988 [https://perma.cc/9PAW-WZFA]. At least 86 Chinese patients have
had their genes edited by CRISPR-Cas9 so far. Preetika Rana et al., China, Unhampered by
Rules, Races Ahead in Gene-Editing Trials, WALL STREET J. (Jan. 21, 2018, 2:19 PM), https://
www.wsj.com/articles/china-unhampered-by-rules-races-ahead-in-gene-editing-trials-151656
2360?mg=prod/accounts-wsj [https://perma.cc/GDZ5-KK4Y].
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embryos,14 and human trials of a CRISPR-based treatment for a
blood disorder will begin in Europe in 2018.15
Most of the legal scholarship on CRISPR-Cas9 has focused on the
patent dispute between the University of California and The Broad
Institute,16 on how the use of CRISPR should be regulated,17 or on
the ethical concerns about how CRISPR should be used.18 Legal
scholarship has not yet addressed the question that this Note seeks
to answer: are therapeutic applications of CRISPR-Cas9 patent-
able? Previous articles have examined the patentability of the
processes required to make CRISPR-Cas9 and transcribe it into
other organisms, but have not examined the patentability of
14. Lauren Neergaard, First Embryo Gene-Repair Holds Promise for Inherited Disease,
ASSOCIATED PRESS (Aug. 2, 2017), https://apnews.com/fcf52fde924d430ca9441aa401c259ed/
First-embryo-%20gene-repair-holds-promise-for-inherited-disease [https://perma.cc/S26K-
4VNQ].
15. Clara Rodrígez Fernández, CRISPR Therapeutics Plans First CRISPR/Cas9 Clini-
cal Trial in Europe for 2018, LABIOTECH.EU (Dec. 13, 2017), https://labiotech.eu/crispr-
therapeutics-clinical-trials/ [https://perma.cc/3MCR-54FQ].
16. See Kristin Beale, The CRISPR Patent Battle: Who Will be “Cut” out of Patent Rights
to One of the Greatest Scientific Discoveries of our Generation?, 2015 B.C. INTELL. PROP. &
TECH. F. 1, http://bciptf.org/wp-content/uploads/2016/02/KBeale-CRISPR.pdf [https://perma.cc/
W5Z5-NY4U]; James W. Sanner, Note, The Struggle for CRISPR: A Billion Dollar Question
in Intellectual Property, 2016 U. ILL. J.L. TECH. & POL’Y 431 (2016). The patent dispute
between the Broad Institute and the University of California began in 2013, when both
entities filed for patents on CRISPR-based genetic editing systems. Broad Inst., Inc. v.
Regents of the Univ. of Cal., No. 106,048 (DK) (P.T.A.B. Feb. 15, 2017). The University of
California, which was first to file for the patent, filed a patent interference claim, alleging that
Broad’s application of CRISPR editing techniques to eukaryotic cells was an obvious ap-
plication of the University’s patented process. Id. The Patent Trial and Appeal Board (PTAB)
sided with Broad, finding that their use of CRISPR in eukaryotic cells was non-obvious, and
therefore did not interfere with the University of California’s patent. Id. The University of
California appealed this decision to the Federal Circuit, which affirmed the PTAB. Regents
of the Univ. of Cal. v. Brand Inst., Inc., No. 2017-1907, 2018 WL 4288968, at *1 (Fed. Cir.
Sept. 10, 2018).
17. See Evita V. Grant, FDA Regulation of Clinical Applications of CRISPR-CAS Gene
Editing Technology, 71 FOOD & DRUG L.J. 608, 609 (2016); Sarah Ashley Barnett, Comment,
Regulating Human Germline Modification in Light of CRISPR, 51 U. RICH. L. REV. 553, 555
(2017); Teddy Ellison, Note, Why Genetics is CRISPR Than It Used to Be: Helping the Novice
Understand Germ Line Modification and its Serious Implications, 26 S. CAL. INTERDIS. L.J.
595, 596 (2017); Adam J. Gross, Comment, Dr. Frankenstein, Or: How I Learned to Stop
Worrying and Love CRISPR-Cas9, 56 JURIMETRICS J. 413, 414 (2016).
18. See G. Edward Powell III, Embryos as Patients? Medical Provider Duties in the Age
of CRISPR/Cas9, 15 DUKE L. & TECH. REV. 344, 346 (2017); Natalie Ram, Science as Speech,
102 IOWA L. REV. 1187, 1193 (2017); Tara R. Melillo, Note, Gene Editing and the Rise of
Designer Babies, 50 VAND. J. TRANSNAT’L L. 757, 762 (2017); Ellison, supra note 17.
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CRISPR-Cas9 systems in the context of providing medical care by
editing viral, bacterial, or human DNA.19
It is not clear that these CRISPR-Cas9 applications would qualify
as patentable subject matter under the traditional tests for patent-
ability.20 This issue is further complicated because federal law pre-
vents patents from issuing “on a claim directed to or encompassing
a human organism,” and it is not obvious whether CRISPR-Cas9
systems cross that line.21 The legislative history of the Act suggests
that Congress designed this provision to prevent “human embryos
and fetuses” from being patented.22 However, the law’s authors did
intend that “genes, stem[ ] cells, [and] animals with human genes”
would remain patentable.23 This suggests that researchers seeking
to create scalable CRISPR-Cas9 treatments for a broad range of
human ailments will have to do more than simply convince the FDA
that their therapy is safe24: they will also likely have to litigate the
question of whether their treatment is patentable subject matter
under current federal law.
This Note seeks to answer that question, and concludes that while
antibacterial and antiviral CRISPR-Cas9 treatments are patentable,
treatments that edit somatic or germline cells are not. Part I will
provide biological context, explaining what CRISPR-Cas9 is, how it
19. See supra notes 16-18 and accompanying text. This Note focuses on CRISPR-Cas9’s
potential as a treatment for human illness. CRISPR-Cas9 can also be used to detect illnesses.
See Janice S. Chen et al., CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-
Stranded DNase Activity, SCIENCE (Feb. 15, 2018), http://science.sciencemag.org/content/early/
2018/02/14/science.aar6245.full.pdf [https://perma.cc/YMC8-HUQR] (describing a CRISPR-
Cas9 variant that “enables rapid and specific detection of human papillomavirus”); Jonathan
S. Gootenberg et al., Multiplexed and Portable Nucleic Acid Detection Platform With Cas13,
Cas12a, and Csm6, SCIENCE (Feb. 15, 2018), http://science.sciencemag.org/content/sci/early/
2018/02/14/science.aaq0179.full.pdf [https://perma.cc/4JKK-RUK6] (describing CRISPR-Cas9
variants that “can detect Dengue or Zika virus”). 
20. See infra Part II.A.
21. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
22. See MANUAL OF PATENT EXAMINING PROCEDURE § 2105 (9th ed. 2015), which noted
that the legislative history provides some clarity as to the meaning of the AIA. The Manual
quotes a statement that observes that “[t]he U.S. Patent Office has already issued patents on
genes, stems cells, animals with human genes, and a host of non-biologic products used by
humans, but it has not issued patents on claims directed to human organisms, including
human embryos and fetuses.” Id. (quoting 157 CONG. REC. E1177-04 (2011) (statement of Rep.
Weldon)).
23. Id.
24. See Food & Drug Admin., supra note 12.
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differs from other genetic editing technologies, and how it may be
used as a treatment for human illness in the future. Part II will
provide legal context, explaining the current legal landscape for pat-
ents based on human biology. Part II will also provide a background
on U.S. patent law, describe the patentability of embryos, DNA, and
stem cells, and summarize some of the scholarship on the patent-
ability of CRISPR-Cas9.
Part III will attempt some line-drawing. Are CRISPR-based treat-
ments patentable? Are they too directed at a human organism to be
patented? Does the answer change depending on the therapeutic use
the DNA is put to? Part III will conclude that CRISPR-Cas9 systems
used to treat viral or bacterial infections are patentable because
they are analogous to non-biologic drugs, but CRISPR-Cas9 systems
used to alter genetic mutations or for germline therapies are not
patentable because they are directed at a human organism. Part IV
considers and rejects some counterarguments to the normative
framework outlined in Part III.
I. SCIENTIFIC BACKGROUND
In order to be patentable, an invention must be, among other
things, a “new and useful,”25 “novel [ ],”26 and “non-obvious”27 thing
or process.28 To determine whether an invention meets these re-
quirements, a patent examiner looks at the “prior art”29—the sci-
entific background that undergirds the patent application.30 Because
the scientific background is useful not just for determining whether
CRISPR-Cas9 is patentable, but also for defining precisely what it
is, this Part will provide a basic introduction to CRISPR-Cas9 and
its therapeutic applications.
25. 35 U.S.C. § 101 (2012).
26. Id. § 102.
27. Id. § 103.
28. Id. § 101.
29. See, e.g., id. § 102.
30. In patent law, the prior art is “[k]nowledge that is publicly ... available on the date of
invention[,] to a person of ordinary skill” in that field. Prior Art, BLACK’S LAW DICTIONARY (9th
ed. 2009).
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A. What is CRISPR-Cas9?
Scientists have been using genome-editing technologies since
1994.31 Genome-editing technologies “give scientists the ability to
change an organism's DNA.”32 The three genome-editing technol-
ogies primarily in use today are zinc-finger nucleases (ZFNs),
transcription activator-like effector nucleases (TALENs), and
CRISPR-Cas9.33 Of these three, CRISPR-Cas9 has the greatest ther-
apeutic potential because it is the most scalable—when compared
to ZFNs and TALENs, CRISPR-Cas9 systems are cheap, easy to
produce, efficient, and can easily be tailored to edit multiple genes
at a single time.34
CRISPR are short sequences of DNA that code for a guide RNA
(gRNA) that is then paired with a CRISPR-associated (Cas) protein,
an enzyme35 that acts like a pair of molecular scissors and cleaves36
31. See Philippe Rouet et al., Introduction of Double-Strand Breaks into the Genome of
Mouse Cells by Expression of a Rare-Cutting Endonuclease, 14 MOLECULAR & CELLULAR
BIOLOGY 8096, 8096 (1994).
32. Nat’l Inst. of Health, What are Genome Editing and CRISPR-Cas9?, GENETICS HOME
REFERENCE (June 5, 2018), https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting
[https://perma.cc/V2LQ-BK9Q].
33. Thomas Gaj et al., Genome-Editing Technologies: Principles and Applications, COLD
SPRING HARBOR PERSP. BIOLOGY 1, 1 (2016), http://cshperspectives.cshlp.org/content/8/12/
a023754.full [https://perma.cc/4NQB-9SSZ]. While scientists have been using genome-editing
technologies for decades, these three represent a significant advance over prior technology
because they can target specific sites on DNA. Id. at 7. “Before the emergence of [these tech-
nologies], genetically modifying mammalian cell lines was labor intensive, costly, and often
times limited to laboratories with specialized expertise. However, with the advent of cost-
effective and user-friendly gene-editing technologies, custom cell lines carrying nearly any
genomic modification can now be generated ... simply.” Id.
34. E.g., Jim Yeadon, Pros and Cons of ZNFs, TALENs, and CRISPR/Cas, JACKSON
LABORATORY, https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-cons-of-
znfs-talens-and-crispr-cas [https://perma.cc/BS84-WZ4U].
35. An enzyme is a protein produced by a cell to facilitate a chemical reaction (in this case,
breaking the bonds that hold the DNA molecule together). Enzyme, BIOLOGY ONLINE DICTION-
ARY, https://www.biology-online.org/dictionary/Enzyme [https://perma.cc/A5ZD-MLXP].
36. In genetics, “cleave” indicates a chemical reaction that cuts a larger molecule in-
to smaller ones. Cleavage, BIOLOGY ONLINE DICTIONARY, https://www.biology-online.org/
dictionary/Cleavage [https://perma.cc/46LY-NN6M].
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target DNA at very specific locations in the genome.37 The gRNA
steers the Cas to the appropriate cutting site on the target DNA.38
CRISPR-Cas9 originally evolved as an immune response in bac-
teria; it protected the bacteria from viral infection.39 The bacteria
would incorporate short sequences of DNA from viruses that had
infected them into their own genetic code.40 The bacteria could then
use the incorporated viral DNA to create an “immune memory” that
helped it recognize an infection from the same virus in the future.41
The incorporated viral DNA would be used as a model for a gRNA.42
That gRNA could then guide a Cas9 to the virus, in order to destroy
it.43 The gRNA would direct the Cas9 to the target site on the virus’s
DNA, where the Cas9 would create a double-strand break in the
viral DNA, destroying it and ending the infection.44
CRISPR-Cas9 was first discovered in 2000 by researchers in
Spain,45 but its genetic editing potential was not publicly recognized
until 2012, when scientists at the University of California, Berkeley
published a paper in the journal Science detailing the first complete
catalogue of the CRISPR-Cas9 system as found in bacteria.46
37. See Koo & Kim, supra note 8, at 38. For images of Cas9 at work, see Mikihiro Shibata
et al., Real-Space and Real-Time Dynamics of CRISPR-Cas9 Visualized by High-Speed Atomic
Force Microscopy, 8 NATURE COMM. 1, 2 (2017), https://www.nature.com/articles/s41467-20%
017-01466-8.pdf [https://perma.cc/3C2M-2SE3]. The full video is available in GIF format on
the Twitter page of one of the paper’s authors. Hiroshi Nishimasu (@hnisimasu), TWITTER
(Nov. 10, 2017, 5:32 AM), https://twitter.com/hnisimasu/status/928933260159197184 [https://
perma.cc/3LVF-ETJV]. An article published in The Atlantic includes an excellent breakdown
of the video, with screen captures that show CRISPR-Cas9 creating a double-strand break in
the DNA. Sarah Zhang, An Astonishing Video Shows CRISPR Editing DNA in Real Time,
ATLANTIC (Nov. 13, 2017), https://www.theatlantic.com/science/archive/2017/11/ crispr-video-
real-time/545603/ [https://perma.cc/57VE-YLHG].
38. Koo & Kim, supra note 8, at 38.
39. Sternberg & Doudna, supra note 9, at 568. 
40. Rodolphe Barrangou, The Roles of CRISPR—Cas Systems in Adaptive Immunity and
Beyond, 32 CURRENT OPINION IMMUNOLOGY 36, 36-37 (2015).
41. Id. at 36. This is similar to the way that human antibodies work. Id.; see also The
Defense Mechanisms of the Adaptive Immune System, PUBMED HEALTH, https://www.ncbi.nlm.
nih.gov/pubmedhealth/PMH0072581/ [https://perma.cc/C7GE-JSM7].
42. Barrangou, supra note 40, at 36-37.
43. Id.
44. Id. For images of this process, see Shibata et al., supra note 37, at 2-3.
45. See Francisco J.M. Mojica et al., Intervening Sequences of Regularly Spaced Pro-
karyotic Repeats Derive from Foreign Genetic Elements, 60 J. MOLECULAR EVOLUTION 174, 174
(2004).
46. Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adap-
tive Bacterial Immunity, 337 SCIENCE 816, 820 (2012).
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CRISPR-Cas9 is incredibly useful as a genetic editing tool because
it is highly accurate.47 Because the CRISPR-Cas9 gRNA is twenty
nucleotides48 long, and each nucleotide will pair exactly with a
nucleotide on the target DNA, there is less than a one in one trillion
chance that the Cas9 will cleave the DNA at the wrong site.49
Cleaving DNA at only the intended target site is critical because
any off-target editing50 risks damaging functioning DNA and cre-
ating serious, potentially lethal side-effects.51
CRISPR-Cas9’s enormous therapeutic potential does not derive
merely from the fact that it can damage DNA at very specific
places.52 This capacity by itself is not unique, or even necessarily
very helpful.53 After all, what frequently makes carcinogens
47. See, e.g., Yeadon, supra note 34.
48. Koo & Kim, supra note 8, at 38.
49. DNA is comprised of four nucleotides: adenine, cytosine, guanine, and thymine.
Nucleotides and Bases, GENETICS GENERATION, http://knowgenetics.org/nucleotides-and-bases/
[https://perma.cc/92NY-BN8N]. Each nucleotide pairs with exactly one other nucleotide. Id.
Thus there is a one in four chance that a single nucleotide of the gRNA will match with a
nucleotide of the target DNA. See id. Since (1/4)^20 = 1/1,099,511,600,000, there is a less than
one in one trillion chance that the target DNA would contain two twenty-nucleotide sequences
that are exactly the same. Of course, this assumes that DNA nucleotides are arranged
randomly. In fact, scientists have found that many nucleotide sequences are repeated
throughout the genome, and that these repeated sequences can serve important functions.
E.g., James A. Shapiro & Richard von Sternberg, Why Repetitive DNA is Essential to Genome
Function, 80 BIOLOGICAL REVIEWS 227, 243 (2005). Indeed, CRISPR’s name itself reveals that
nucleotide sequences are not randomly distributed: remember that CRISPR is an acronym for
“clustered regularly interspaced short palindromic repeats.” Koo & Kim, supra note 8, at 38.
50. In the genetics context, off-target editing occurs when a genetic editing technology
“produce[s] unwanted DNA mutations at sites other than the desired target.” Sue McGreevey,
Off-Target Gene Editing, HARV. MED. SCH. (June 25, 2013), https://hms.harvard.edu/news/
genetics/target-gene-editing-6-25-13 [https://perma.cc/RAP4-U9KE].
51. See Koo & Kim, supra note 8, at 39, 43. Compare Kellie A. Schaefer et al., Unexpected
Mutations After CRISPR-Cas9 Editing in vivo, 14 NATURE METHODS 547, 547-48 (2017)
(reporting a study that purportedly showed thousands of off-target genetic mutations al-
legedly caused by CRISPR-Cas9 in mice treated with the technology), with Vivek Iyer et al.,
No Unexpected CRISPR-Cas9 Off-Target Activity Revealed by Trio Sequencing of Gene-
Edited Mice 5 (Feb. 9, 2018) (unpublished manuscript) (available at https://www.biorxiv.org/
content/early/2018/02/09/263129.full.pdf+html) [https://perma.cc/4FW4-9QEJ] (concluding
that any off-target mutations in mice treated by CRISPR-Cas9 are not statistically significant
from the background level of mutation found in mice untreated by CRISPR-Cas9). 
52. See Koo & Kim, supra note 8, at 39-42. This is not to say that this aspect of CRISPR-
Cas9 is not useful. The mere destruction of DNA can be very useful as a treatment for viral
and bacterial infections. See id.; infra Parts I.B.1, I.B.2.
53. See Yeadon, supra note 34.
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carcinogenic is their ability to damage DNA.54 CRISPR-Cas9 has
enormous therapeutic potential because its highly specific cutting
ability targets extremely specific sequences of DNA, and can be
paired with processes that insert desirable DNA at the target site,
creating the potential to replace a defective gene with a functioning
one.55 This means that CRISPR-Cas9 could serve as a cure to not
just infectious diseases, but also inherited ones.56
Recent research by scientists at Stanford University indicates
that CRISPR-Cas9 in its current iteration may have limited effec-
tiveness in treating human disease.57 The researchers discovered
that because Cas9 (the cutting protein) is present in bacteria that
frequently infect humans, we may have developed an immune
response to it.58 However, the scientists concede that while their
study is an important reminder to be cautious with CRISPR-Cas9,
it is “not a deal-breaker, even for people with immunity to [Cas9],
because there are other [cutting] proteins that could be adapted to
do the job.”59 The researchers also cautioned that their results only
implicate therapeutic applications of CRISPR-Cas9 where the Cas9
protein may come in contact with the human immune system.60
Indeed, “[s]ome of the first human experiments in the U.S. ... will
use the Cas9 proteins on blood cells outside the body, so there’s little
chance the immune system will cause any trouble.”61 In the mean-
time, researchers can work to determine the most effective means
of deploying CRISPR-Cas9 as a therapy.62
54. See Known and Probable Human Carcinogens, AM. CANCER SOC’Y (Nov. 3, 2016),
https://www.cancer.org/cancer/cancer-causes/general-info/known-and-probable-human-
carcinogens.html [https://perma.cc/4KPC-25DE].
55. Yeadon, supra note 34.
56. Koo & Kim, supra note 8, at 40.
57. See Carsten T. Charlesworth et al., Identification of Pre-Existing Adaptive Immunity
to Cas9 Proteins in Humans 2-3 (Jan. 5, 2018) (unpublished manuscript) (available at https://
www.biorxiv.org/content/biorxiv/early/2018/01/05/243345) [https://perma.cc/MLJ3-VZ6A].
58. Id. at 5-6.
59. Faye Flam, Scientists Don’t Fear a New Crispr Snag, BLOOMBERG (Jan. 23, 2018,
3:27 PM), https://www.bloomberg.com/view/articles/2018-01-23/gene-scientists-don-t-fear-the-
latest-crispr-snag [https://perma.cc/SFL9-US4M].
60. Id.; see also Charlesworth et al., supra note 57, at 7 (“Pre-existing adaptive immune
responses may be of less concern for ex vivo therapies that involve the use of Cas9 to edit cells
outside of direct contact with the human immune system.”).
61. Flam, supra note 59 (emphasis added).
62. See id.
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B. Therapeutic Applications
CRISPR-Cas9 could be used to treat human illness and disease63
in four basic ways: it has potential to (1) combat viral infections, (2)
fight bacterial infections, (3) edit somatic (non-germline)64 cells, and
(4) edit germline cells.65 Each therapeutic application could be
immensely important. Using CRISPR to treat viral infections could
mean a cure to HIV/AIDS.66 Using it to treat bacterial infections
could mean a solution to antibiotic-resistant tuberculosis.67 Editing
somatic cells using CRISPR could mean an end to muscular dys-
trophy, or a cure for cancer.68 Editing germline cells could mean an
end to infertility and a preemptive cure for all inheritable genetic
diseases.69
1. Viral Infections
Using CRISPR-Cas9 to treat viral infections such as HIV is “one
of the promising new approaches in gene therapy.”70 Researchers
have used CRISPR-Cas9 to treat a variety of viruses, including HIV,
HPV, herpes, and hepatitis B.71 Treatment works in one of two
ways: “Cas9 can target [either] viral genes or host genes that encode
essential receptors to suppress infection [by] viruses.”72 Human clin-
ical trials using ZFNs, another genome-editing treatment, have
proved effective at treating HIV.73 Laboratory trials using CRISPR-
63. As described above, this Note focuses on the use of CRISPR-Cas9 to treat human
illnesses, and not on its use in detecting human illness. See supra note 19.
64. For more on the difference between somatic and germline cells, see Himanshu Bhatia,
Stem Cells, ROSWELL PARK CANCER INST., https://www.roswellpark.org/sites/default/files/
Bhatia_11_8_12.pdf [https://perma.cc/E386-RH6C]. Essentially, somatic cells are the cells that
are found in the vast majority of our organs, whereas germline cells are “the cells that are
responsible for reproduction,” such as egg and sperm cells. Id.
65. Koo & Kim, supra note 8, at 39.
66. See id. at 39, 41.
67. See id. at 40; M. Doerflinger et al., CRISPR/Cas9—The Ultimate Weapon to Battle
Infectious Deiseases?, CELLULAR MICROBIOLOGY, no. 19, Feb. 2017, at 3, https://onlinelibrary-
wiley-com.proxy.wm.edu/doi/full/10.1111/cmi.12693 [https://perma.cc/U9FD-PY6F].
68. See Koo & Kim, supra note 8, at 40, 43.
69. See id. at 40.
70. Id. at 39.
71. Id. at 39, 41.
72. Id. at 39.
73. Id.
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Cas9 to treat viruses have also been effective, but in some trials in
which researchers targeted only one HIV gene, the virus managed
to evolve into a CRISPR-Cas9-resistant mutant.74 Researchers have
suggested that the most effective CRISPR-Cas9 treatments for viral
infections will target multiple genes to ensure complete removal of
the virus.75
CRISPR-Cas9 has already been used to cure HIV (although not
in humans).76 The scientists in that study used three different
populations of HIV-infected lab mice, “including a ‘humanized’
[population,] where human immune cells infected with the virus
were transplanted in lab mice.”77 The CRISPR-Cas9 treatment
proved effective in all three populations; the treatment removed the
HIV DNA from all of the mice.78 Buoyed by their success, the re-
searchers hope to transition next to trials in primates, with the
ultimate goal of beginning human trials by 2020.79
Scientists at Temple University have already demonstrated that
CRISPR-Cas9 can also be used to effectively cure HIV in human
cells.80 They used CRISPR-Cas9 to remove the entire HIV gene from
infected human immune cells in laboratory conditions.81 It is im-
portant to note that these were not clinical trials; the tests were
conducted on cell cultures (groups of cells grown outside the body)
in a lab.82 Nonetheless, the tests are an important step forward in
using CRISPR-Cas9 to treat HIV.
74. Id. at 40.
75. Id.
76. Brian Mastroianni, Researchers Use Gene Editing to Eliminate HIV Infection in Mice,
CBS NEWS (May 3, 2017, 10:46 PM), https://www.cbsnews.com/news/gene-editing-crispr-
remove-hiv-infection-in-mice/ [https://perma.cc/WFX8-MD3Y].
77. Id.
78. Id.
79. See Dan Avery, How a Transplant “Cured” This Man of HIV, NEWNOWNEXT (Nov. 12,
2017), www.newnownext.com/how-a-transplant-cured-this-man-of-hiv/11/2017/ [https://perma.
cc/4M94-HX33]; Mastroianni, supra note 76.
80. Rafal Kaminski et al., Elimination of HIV-1 Genomes from Human T-lymphoid Cells
by CRISPR/Cas9 Gene Editing, 6 SCI. REP. 1, 10 (2016).
81. Id. at 2.
82. Id.
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2. Bacterial Infections
CRISPR-Cas9 could be used to treat bacterial infections by “tar-
get[ing] bacterial genes and thereby inhibit[ing] bacterial growth.”83
This is a particularly potent therapy when deployed against anti-
biotic-resistant bacteria, which cannot be effectively treated using
standard medicines.84 DNA encoding the CRISPR-Cas9 treatment
is delivered to the bacteria through a specially engineered virus.85
This style of treatment is especially advantageous because the
CRISPR-Cas9 system is designed to target only bacterial genes.86
Therefore, there is reduced risk that the Cas9 will damage human
DNA, which does not contain the bacterial DNA sequence.87
Researchers at Harvard University have already demonstrated
that CRISPR-Cas9 can be used to kill antibiotic-resistant tuberculo-
sis in laboratory conditions.88 The scientists initially wanted to pair
the Cas9 already present in tuberculosis cells with a custom gRNA
to initiate gene knockdowns that would kill the bacteria.89 However,
they discovered that this was not an efficient treatment.90 Instead,
they used Cas9 from another bacteria, which they discovered “typ-
ically achieves 20-100 fold knockdown of [tuberculosis] gene ex-
pression.”91
Scientists in China have demonstrated another way to use
CRISPR-Cas9 to prevent tuberculosis: editing tuberculosis resis-
tance genes into an animal’s genome.92 The researchers used a
83. Koo & Kim, supra note 8, at 40.
84. See id.
85. Id.
86. Id.
87. Id.
88. Jeremy M. Rock et al., Programmable Transcriptional Repression in Mycobacteria
Using an Orthogonal CRISPR Interference Platform, 2 NATURE MICROBIOLOGY 1, 4 (2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302332/pdf/nihms838633.pdf [https://perma.
cc/VWN9-UZJJ]; see also Atul K. Singh et al., Investigating Essential Gene Function in
Mycobacterium tuberculosis Using an Efficient CRISPR Interference System, 44 NUCLEIC
ACIDS RES., no. 18, July 2016, at 2, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062980/
[https://perma.cc/X3FF-38BA] (describing similar results).
89. Rock et al., supra note 88, at 2-3.
90. Id.
91. Id.
92. Tuberculosis-Resistant Cows Developed for the First Time Using CRISPR Gene-Editing
Technology, PHYS.ORG (Jan. 31, 2017), https://phys.org/news/2017-01-tuberculosis-resistant-
cows-crispr-technology.html [https://perma.cc/AN5L-RY2L].
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variant of CRISPR-Cas9 called CRISPR-Cas9n to insert a tuber-
culosis-resistant gene into a cow’s reproductive cell.93 That cell was
then combined with a regular cow egg, forming a fetus that was
nurtured in a lab before it was inserted into a cow that then had a
regular pregnancy.94 When the genetically altered cows were later
infected with tuberculosis, they showed a greater resistance to it
than animals that had an unedited genome.95 This is an example of
using CRISPR-Cas9 germline editing to achieve antibiotic effects.96
3. Editing Somatic Cells
Researchers have conducted numerous studies testing CRISPR-
Cas9 systems designed to edit genetic diseases out of human cells.97
Since CRISPR-Cas9 does not naturally occur in human cells, the
gRNA and Cas9 either need to be delivered to the cells directly, or
DNA coding for them needs to be inserted into the DNA of the cells
so that the cells themselves produce the gRNA and the Cas9.98
Delivering the gRNA/Cas9 complex directly to the cells has many
advantages, because then the cells’ defenses destroy the complex
within 24 hours, which helps to limit off-target effects.99 However,
this delivery method has only limited success (because not all cells
obtain the Cas9/gRNA complex), so viral delivery is widely consid-
ered to be the superior method.100
Scientists at the University of California, Berkeley, announced in
2017 that they had successfully used CRISPR-Cas9 to repair the
mutation that causes muscular dystrophy in mice.101 The scientists
injected mice that had muscular dystrophy with a CRISPR-Cas9
variant called CRISPR-Gold, a new CRISPR delivery mechanism
93. Id.
94. Id.
95. Id.
96. See infra Part I.B.4.
97. Koo & Kim, supra note 8, at 40.
98. Id.
99. Id. The longer the complex is active in the cell, the greater the chances that it could
create an off-target effect. See id.
100. Id.
101. Brett Israel, CRISPR-Gold Fixes Duchenne Muscular Dystrophy Mutation in Mice,
BERKELEY NEWS (Oct. 3, 2017), http://news.berkeley.edu/2017/10/03/crispr-gold-fixes-duchenne-
muscular-dystrophy-mutation-in-mice/ [https://perma.cc/DD35-88U2].
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that they had designed.102 The benefit of the CRISPR-Gold delivery
mechanism is that it effectively transports the Cas9/gRNA complex
into the cell intact, vitiating the need for a viral delivery mecha-
nism.103 Researchers found that the CRISPR-Gold treatment “led to
an 18-times-higher correction rate and a two-fold increase in a
strength and agility test [in treated mice when] compared to control
groups.”104
4. Editing Germline Cells
CRISPR-Cas9 could also be used to edit germline cells.105 The
process works in a largely similar manner to edits made to somatic
cells.106 The CRISPR-Cas9 complex is injected into the sperm or egg
cells, or into the embryo very shortly after fertilization.107 Because
the injection occurs so early in the life of the organism, the hope is
that the corrected DNA will spread to most or all of the cells as the
newly fertilized egg begins to divide.108 This treatment method can
sometimes be ineffective due to “mosaicism,” when the DNA edits
are present in some of the cells, but not others.109 Researchers
studying mice have found two to one hundred percent of cells in
germline edited mice expressed the target sequence of DNA, rather
than the corrected sequence that the scientists were trying to
insert.110 Editing germline cells also leads to the possibility that
edited DNA could be passed on to the next generation.111 If edited
DNA is expressed in cells that manufacture sperm or eggs, then the
genetic edits will be passed on to future generations.112
102. Id.
103. Id. This was ground-breaking news, because all CRISPR-Cas9 treatments must be
able to enter cells in order to be effective. See generally Koo & Kim, supra note 8.
104. Israel, supra note 101.
105. Koo & Kim, supra note 8, at 40. This is where moral opponents of CRISPR take their
firmest stand. See Cokley, supra note 7.
106. Koo & Kim, supra note 8, at 40.
107. Id.
108. See id.
109. Id.
110. Id.
111. Id.
112. See id.
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In a study similar to the one conducted by the Berkeley muscular
dystrophy researchers, scientists at the University of Texas used
CRISPR-Cas9 to cure muscular dystrophy in mice.113 These re-
searchers, however, injected newly fertilized mouse eggs that had
the muscular dystrophy genes with the CRISPR-Cas9 system.114
While they did see a great deal of mosaicism in the adult mice, they
noted that the mice actually displayed stronger muscles than would
be expected based solely on gene expression.115 They surmised that
having even some properly working cells was an important treat-
ment outcome, because those properly functioning cells could have
a disproportionate positive impact on the mice.116
II. LEGAL LANDSCAPE
The American patent system is designed to encourage intellectu-
al inquiry by protecting ideas and inventions.117 Indeed, Congress
has granted patent protection to “[w]hoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,” subject only
to certain “conditions and requirements.”118 This Part will detail sev-
eral of those requirements, focusing primarily on what is required
for an invention to be patent-eligible subject matter.
A. General Requirements for Patentability
Section 101 of the Patent Act mandates that in order to qualify for
patent protection, the invention first needs to be patent-eligible sub-
ject matter—something for which a patent is even allowed to issue
(generally a physical object or a process).119 However, patents will
not issue for inventions that merely describe laws of nature.120 The
113. Chengzu Long et al., Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-
Mediated Editing of Germline DNA, 345 SCIENCE 1184, 1184 (2014).
114. Id. at 1184-85.
115. Id. at 1185-87.
116. Id.
117. See U.S. CONST. art. I, § 8, cl. 8; Nuno Pires de Carvalho, The Primary Function of
Patents, 2001 J.L. TECH. & POL’Y 25, 29 (2001).
118. 35 U.S.C. § 101 (2012). 
119. See id.
120. See, e.g., Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 72 (2012).
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Supreme Court articulated this rule in Mayo Collaborative Services
v. Prometheus Laboratories, Inc., where it held that “[i]f a law of
nature is not patentable, then neither is a process reciting a law of
nature, unless that process has additional features that provide
practical assurance that the process is more than a drafting effort
designed to monopolize the law of nature itself.”121 However, because
“all inventions at some level embody, use, reflect, rest upon, or apply
laws of nature,”122 the Court cautioned that “an application of a law
of nature ... to a known structure or process may well be deserving
of patent protection.”123
In Alice Corp. v. CLS Bank International, the Court explained
that a two-step process should be used to determine whether a
patent improperly embodies a law of nature.124 First, a court has to
decide if the patent contains an abstract idea.125 Next, it must de-
termine whether the patent contains a sufficient “inventive concept”
beyond a mere instruction to apply the rule of nature.126 If the
patent contains a sufficient inventive concept, and does not merely
describe situations in which the law of nature should be applied,
then patent protection is appropriate.127
Assuming that a patent application covers appropriate subject
matter, it must still meet several other requirements for patentabil-
ity.128 In order to be patentable, an invention must be useful,129
novel,130 non-obvious,131 and properly disclosed.132
121. Id. at 77.
122. Id. at 71.
123. Id. (quoting Diamond v. Diehr, 450 U.S. 175, 187 (1981)).
124. 134 S. Ct. 2347, 2355 (2014).
125. Id.
126. Id.
127. Id.
128. See, e.g., 35 U.S.C. § 102 (2012).
129. Id. § 101.
130. Id.
131. See, e.g., Graham v. John Deere Co., 383 U.S. 1, 14 (1966).
132. 35 U.S.C. § 112 (2012).
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B. The America Invents Act Regime
The Leahy-Smith America Invents Act (AIA) adds some addi-
tional conditions for researchers to meet in order for their invention
to qualify as patent-eligible subject matter.133 The AIA prevents
patents from “issu[ing] on a claim directed to or encompassing a
human organism.”134 While the AIA is meant to limit patent pro-
tection for certain types of research (and, indeed, seems designed to
prevent that research altogether), it is not meant to prevent patents
for all inventions that could be consumed or used by humans.135
Indeed, the drafters of the AIA specifically noted that patents
should be allowed to issue “on genes, stem cells, animals with hu-
man genes, and a host of non-biologic products used by humans.”136
This means that while pharmaceuticals, which at a minimum have
a strong relationship with human organisms, are able to gain patent
protection,137 human embryos are not.138
The AIA did not radically change U.S. Patent and Trademark
Office (USPTO) policy on the patentability of human organisms.139
Indeed, in a letter to Congress describing pre-AIA USPTO policy,
Director of the USPTO James Rogan said that the AIA was “fully
consistent with USPTO's policy on the non-patentability of human
life-forms.”140 Director Rogan further elaborated on long-standing
USPTO policy, saying:
The USPTO’s policy of rejecting patent application claims that
encompass human life-forms, which the Weldon Amendment
133. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 33(a), 125 Stat. 340 (2011).
134. Id.
135. See MANUAL OF PATENT EXAMINING PROCEDURE, supra note 22, at § 2105.
136. Id. (quoting 157 CONG. REC. E1177-04 (2011) (statement of Rep. Weldon)).
137. E.g., U.S. Patent No. 5,108,993 (issued Apr. 28, 1992) (a patent on a popular anti-HIV
drug not declared invalid under long-standing USPTO policy or the AIA).
138. MANUAL OF PATENT EXAMINING PROCEDURE, supra note 22, at § 2105 (quoting 157
CONG. REC. E1177-04 (2011) (statement of Rep. Weldon)).
139. See 157 CONG. REC. E1177 (daily ed. June 23, 2011) (statement of Rep. Smith) (“[F]or
over two decades, USPTO has had an internal policy that human beings at any stage of devel-
opment are not patentable subject matter under 35 U.S.C. Section 101.”).
140. Letter from James Rogan, Dir., U.S. Patent & Trademark Office, to Ted Stevens,
Chairman, Comm. on Appropriations, U.S. Senate (Nov. 20, 2003), http://www.nrlc.org/
archive/Killing_Embryos/Human_Patenting/WeldonamendUSPTO.pdf [https://perma.cc/
AW7G-2M8N].
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elevates to an unequivocal congressional prohibition, applies
regardless of the manner and mechanism used to bring a human
organism into existence (e.g., somatic cell nuclear transfer, in
vitro fertilization, parthenogenesis). If a patent examiner deter-
mines that a claim is directed to a human life-form at any stage
of development, the claim is rejected as non-statutory subject
matter and will not be issued in a patent as such.141
The policy codified in the AIA therefore was consistent with long-
standing USPTO practice, and focused primarily on whole organ-
isms, not on smaller components like stem cells or DNA.142
C. The Law as Applied to Human Biology
USPTO policy and the proscriptions of the AIA143 have not pre-
vented patents from issuing on all technologies arguably targeted
at human biology.144 While human fetuses are consistently not
patentable,145 valid patents have issued on human DNA146 and hu-
man stem cells.147
1. Fetuses
An example of the application of the AIA policy can be found in Ex
parte Kamrava.148 In that case, the Patent Trial and Appeal Board
(PTAB) affirmed the rejection of a patent application for a catheter
that included “an embryo in the distal portion.”149 The patent ap-
plicant argued that the catheter was patent-eligible because the
patent application did not actually encompass an embryo, and the
embryo did not qualify as a part of the human body because “the
141. Id.
142. Id. These, of course, may have other barriers to patentability, including other limits
on patentable subject matter. See, e.g., Mayo Collaborative Servs. v. Prometheus Labs., Inc.,
566 U.S. 66, 72-73 (2012).
143. See supra Part II.B.
144. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595
(2013).
145. See infra Part II.C.1.
146. See infra Part II.C.2.
147. See infra Part II.C.3.
148. See Ex parte Kamrava, No. 2010-010201 (P.T.A.B. Nov. 26, 2012).
149. Id. at 5.
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embryo in the distal portion of the catheter is a non-naturally oc-
curring combination ... which is the product of human ingenuity.”150
The PTAB ruled against the inventor on both arguments.151 They
interpreted the patent application literally, and reasoned that if the
inventor had not meant to include the embryo in the patent, she
would have worded her application differently.152 Additionally, the
PTAB ruled that combining the human embryo with the catheter
did not make it patent-eligible, because “[t]he fact that the claims
cover patent-eligible subject matter ... in combination with patent-
ineligible subject matter ... does not render the claims patent-
eligible.”153 Thus, in order for an invention to be patent-eligible, no
part of it may be directed at a whole human organism.154
2. DNA
The Supreme Court has, however, allowed patents to issue on
genetically modified human DNA.155 In Ass’n for Molecular Pathol-
ogy v. Myriad Genetics, Inc., the Court held that while naturally
occurring DNA is a product of nature and is not patentable, DNA
that does not occur naturally is patentable.156 Myriad dealt with a
company that had discovered the sequence of genes that are impli-
cated in a patient’s risk of developing breast and ovarian cancer.157
They tried to obtain a patent on the typical DNA sequence found in
those genes.158 If granted, the patent would have given them “the
exclusive right to isolate [the relevant] genes,” a step necessary to
determine a patient’s cancer risk.159 The Court reasoned that
150. Id.
151. Id.
152. Id. (“As noted by the Examiner, if Appellant had intended not to encompass an
embryo, the claims could have recited that ‘the distal portion of the catheter is adapted to
receive/hold an embryo.’”).
153. Id. at 6.
154. See id.
155. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595 (2013).
156. Id.
157. Id. at 582-83.
158. Id. at 583-84.
159. Id. at 585. The property interest in the particular gene sequences would have
therefore doubtless been incredibly lucrative for Myriad. See Matthew Herper, Company Will
Raise $1 Billion to Create Blood Test to Detect Cancer, FORBES (Jan. 5, 2017, 4:59 PM), https://
www.forbes.com/sites/matthewherper/2017/01/05/grail-which-aims-to-invent-blood-test-to-
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because the DNA sequences were naturally occurring, Myriad could
not obtain a patent on them.160
The Myriad Court did, however, allow Myriad to obtain a patent
on synthetic DNA that Myriad scientists created in a lab.161 Normal
DNA contains both introns (regions that do not code for proteins)162
and exons (regions that do code for proteins).163 Myriad developed
complementary DNA (cDNA) that contained only exon (coding)
segments.164 The Court ruled that even though cDNA is based on the
naturally occurring DNA sequences, because exon-only DNA
strands do not occur in nature, Myriad was allowed to patent the
cDNA.165
The Federal Circuit recently decided Ariosa Diagnostics, Inc. v.
Sequenom, Inc. on a very similar basis.166 In Sequenom, a compa-
ny had found a way to isolate cell-free fetal DNA (cffDNA) from
maternal blood.167 When a woman is pregnant, a small amount of
cffDNA from her baby is present in her bloodstream.168 The company
designed a test that could use cffDNA to learn about the baby’s
characteristics and to look for genetic abnormalities.169 To test the
DNA effectively, the company employed widely used techniques for
isolating and amplifying DNA.170 The court reasoned that Seque-
nom’s patent failed both prongs of the Alice test; because cffDNA
was “naturally occurring,” and “the method steps were well-under-
stood, conventional and routine,” Sequenom’s process did not add a
sufficient “inventive concept” that would warrant patentability.171
detect-cancer-to-raise-1-billion/#73f2ed553792 [https://perma.cc/WBT4-CVY8].
160. Myriad, 569 U.S. at 591-94.
161. Id. at 594-95.
162. Intron, BIOLOGY ONLINE: DICTIONARY, https://www.biology-online.org/dictionary/Intron
[https://perma.cc/ZBR9-C2JG] (“[An] intron ... [is a] noncoding ... sequence ... that is ... re-
moved from the primary gene transcript and rapidly degraded during maturation of the RNA
product.”).
163. Myriad, 569 U.S. at 595; see also Exon, BIOLOGY ONLINE: DICTIONARY, https://www.
biology-online.org/dictionary/Exon [https://perma.cc/3GDJ-ZCHT] (“[R]egions [of the DNA
that] cod[e] for proteins and which are interrupted by the ... introns.”).
164. Myriad, 569 U.S. at 595.
165. Id.
166. See 788 F.3d 1371 (Fed. Cir. 2015).
167. Id. at 1373.
168. Id.
169. Id.
170. Id.
171. Id. at 1376-77.
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3. Stem Cells
The USPTO has extended patent protection to human stem cells
for the past thirty years.172 However, the federal government has at
times been openly hostile to stem cell research: from 1996 to 2009,
federal funding could not be used for “research that destroyed [or]
created human embryos.”173 President Obama lifted this ban in 2009
with an executive order that allowed funding for research that used
embryos, but only “if th[o]se embryos were created during in vitro
fertilization for reproductive purposes but were no longer needed for
such purposes.”174
Although patents on embryonic stem cells are controversial and
the subject of frequent litigation, the USPTO and the courts have
consistently allowed patents on many stem cell technologies.175
Indeed, researchers have noted a recent increase in patent applica-
tions on stem cell technologies that have therapeutic applications.176
This is in stark contrast to the practice at the European Patent
Office (EPO), which “regards patents on [stem cells] as illegal be-
cause they are patents on a human body or human body part, offend
human dignity, or involve commercial or industrial uses of em-
bryos.”177 However, the willingness in America to grant patents to
some stem cell therapies suggests that the door may be open to
patents on some CRISPR-Cas9-based therapies, as well.178
172. Sonya Davey et al., Interfacing of Science, Medicine and Law: The Stem Cell Patent
Controversy in the United States and the European Union, 3 FRONTIERS CELL &
DEVELOPMENTAL BIOLOGY, art. 71, Nov. 2015, at 3; see also Xuejun H. Parsons et al., Patents
on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human
Embryonic Stem Cells, 1 RECENT PATENTS ON REGENERATIVE MED. 142, 144-45 (2011).
173. Davey et al., supra note 172, at 3.
174. Id.
175. Parsons et al., supra note 172, at 143.
176. Id.
177. Id.
178. The EPO, by contrast, has been hostile to many claims for CRISPR patent protection.
See Kelly Servick, Broad Institute Takes a Hit in European CRISPR Patent Struggle, SCIENCE
(Jan. 18, 2018, 3:30 PM), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hit-
european-crispr-patent-struggle [https://perma.cc/KV22-6NP5].
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D. Scholarly Perspectives on the Patentability of CRISPR-Cas9
Although no commentator has yet written on whether therapeutic
applications of CRISPR-Cas9 are eligible for patent protection,
scholars have written extensively about the patentability of the
CRISPR-Cas9 technology in general.179 Opinion on CRISPR-Cas9’s
patent eligibility has been decidedly mixed, with some commenta-
tors arguing that it should not be patent eligible, and others
maintaining stridently that it should.180
Attorney Benjamin Tuttle contends that in light of Myriad and
Alice, CRISPR-Cas9 systems are not eligible for patent protection
because they “share molecular and genetic structure and function
[with] the naturally-occurring molecules from which they derive.”181
Because they fail the first prong of the Alice test, Tuttle argues that
CRISPR-Cas9 patents are subject to the second prong, which they
also fail.182 Tuttle admits that CRISPR-Cas9 systems used to modi-
fy non-bacterial DNA qualify as an “inventive concept,” but says
that policy considerations, such as the need to promote innovation,
should outweigh the value of protecting the invention.183
 On the other hand, patent attorney Deborah Ku asserts that
CRISPR-Cas9 technologies are patent eligible, and would survive a
challenge to § 101 of the Patent Act because they satisfy the Alice
framework.184 Ku argues that the CRISPR-Cas9 system at issue in
the dispute between the Broad Institute and the University of Cali-
fornia is patentable in part because it “possesses characteristics that
are markedly different from the naturally-occurring counterpart
found in select bacteria.”185 Ku contends that Tuttle fails to consider
179. See supra notes 16-18 and accompanying text.
180. Compare, e.g., Benjamin C. Tuttle, The Failure to Preserve CRISPR-Cas9’s Patent-
ability post Myriad and Alice, 98 J. PAT. & TRADEMARK OFF. SOC’Y 391, 392, 404-05 (2016)
(arguing that CRISPR-Cas9 systems fail both steps of the Alice test and that policy concerns
militate against patentability), with Deborah Ku, The Patentability of the CRISPR-Cas9
Genome Editing Tool, 16 CHI.-KENT J. INTELL. PROP. 408 (2017) (arguing that a patent on
CRISPR-Cas9 should at least survive a § 101 challenge).
181. Tuttle, supra note 180, at 404.
182. Id. at 404-05.
183. Id. at 405.
184. Ku, supra note 180, at 438.
185. Id. at 434.
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that while individual components of the CRISPR-Cas9 system might
be found in nature, “the claimed system as a whole is not.”186
Even if a court finds that the CRISPR-Cas9 system is the same as
what occurs in nature, and therefore fails the first prong of the Alice
test, Ku argues that CRISPR-Cas9 should be patent eligible because
it satisfies the second prong of the test.187 Ku says that the CRISPR-
Cas9 system claimed in the Broad Institute and University of
California patents embodies a sufficient inventive concept to satisfy
the second prong of the test because “getting the naturally-found
CRISPR system ... to work in [non-bacterial] cells required human
intervention.”188 Thus, Ku argues, CRISPR-Cas9 systems should be
patentable, at least as they are defined in the patents filed by the
Broad Institute and the University of California.189
Under the existing regulatory regime, the extent to which the
therapeutic applications of CRISPR-Cas9 are patentable remains
an open question.190 Inventors that attempt to patent DNA-based
therapies face significant barriers to patentability, including
whether their invention already occurs in nature and is therefore
not patent-eligible subject matter,191 and whether they are so widely
used that creating them required no inventive step.192 This is not to
mention one of the largest barriers to patentability for CRISPR-
Cas9 therapies: the AIA’s prohibition against patents “directed to or
encompassing a human organism.”193
III. ARE CRISPR-CAS9 THERAPIES PATENTABLE?
The extent to which patent law (particularly the AIA) allows pat-
ent protection to extend to therapeutic applications of CRISPR-Cas9
systems remains unclear.194 CRISPR-Cas9 therapies face several
186. Id. at 436 (emphasis added).
187. Id. at 437.
188. Id. 
189. Id.
190. See supra notes 180-89.
191. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 591
(2013).
192. See, e.g., Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 134 S. Ct. 2347, 2357 (2014).
193. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
194. See supra Part II.D.
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hurdles to patentability: the applicant must demonstrate that the
therapies (1) do not already occur in nature195 or (2) embody a
sufficient inventive concept,196 and (3) are not “directed to or
encompassing a human organism.”197 As discussed below, some
therapeutic applications of CRISPR-Cas9 will clear these hurdles,
whereas others will not. This Part argues that therapeutic applica-
tions of CRISPR-Cas9 analogous to existing disease treatments
(namely, CRISPR-Cas9 treatments of viral and bacterial infections)
should be granted patent protection, whereas applications that do
not have an existing therapeutic analog (somatic and germline cell
editing) should not.
A. Where Patent Protection Will Apply
CRISPR-Cas9 therapies used to treat viral and bacterial infec-
tions should be granted patent protection. These therapies do not
already occur in nature,198 they are not yet so broadly used that they
do not require an inventive concept,199 and they are not “directed to
or encompassing a human organism”200 in violation of the AIA.201
1. Treating Viral Infections
The anti-viral applications of CRISPR-Cas9 should be granted
patent protection. As explained below, anti-viral applications of
CRISPR-Cas9 clear all three of the hurdles to patentability for
CRISPR-Cas9 therapies. These applications do not occur in nature,
the techniques for delivering the treatment are not widely used,
195. Myriad, 569 U.S. at 591.
196. Alice, 134 S. Ct. at 2357; Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371,
1379-80 (Fed. Cir. 2015).
197. Leahy-Smith America Invents Act (AIA) § 33(a). There are, of course, other
requirements for patentability, such as adequate disclosure, but these are not unique or
particularly challenging in the CRISPR-Cas9 context, so they are not addressed here. See, e.g.,
35 U.S.C. § 112 (2012).
198. See infra notes 202-11 and accompanying text.
199. See infra notes 212-18 and accompanying text.
200. Leahy-Smith America Invents Act (AIA) § 33(a).
201. See infra notes 219-24 and accompanying text.
2018] CUSTOM-EDITED DNA 323
and the treatment is not “directed to or encompassing a human or-
ganism” within the meaning of the AIA.202
As a threshold matter, humans do not naturally use CRISPR-
Cas9 to combat viral infection.203 As the Supreme Court’s decision
in Myriad shows, demonstrating that an invention does not occur in
nature is a low bar.204 A patent applicant need only show that the
invention does not specifically occur in nature.205 In Myriad, even
though the order of the nucleotides in the cDNA came from nat-
urally occurring DNA, Myriad successfully patented the cDNA
sequence because it excluded the introns that were present in the
natural DNA sequence.206
Although some organisms use CRISPR-Cas9 systems as part of
an immune response in nature, they are not naturally part of the
human immune system.207 CRISPR-Cas9 evolved as an immune
response in bacteria.208 Researchers have never recorded CRISPR-
Cas9 as a natural component of the human immune system.209
Therefore, under the Myriad standard,210 inventors should still be
allowed to patent CRISPR-Cas9 systems used to treat viral in-
fections, because the CRISPR-Cas9 system is not a natural part of
the human immune response.211
Even assuming that a court finds that CRISPR-Cas9-based
therapies are naturally occurring, the techniques used to deliver
CRISPR-Cas9 systems into cells are not yet widely used,212 and
thus require a sufficient inventive concept that satisfies the second
prong of the Alice analysis.213 Because human cells do not naturally
contain Cas9 proteins, researchers cannot merely inject gRNA into
virus-infected cells and expect the gRNA to kill the viruses.214
202. Leahy-Smith America Invents Act (AIA) § 33(a); see infra notes 219-24 and accom-
panying text.
203. Sternberg & Doudna, supra note 9, at 568.
204. See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595 (2013).
205. See id.
206. Id.
207. Sternberg & Doudna, supra note 9, at 568.
208. Id.
209. See id.
210. 569 U.S. at 595.
211. See Sternberg & Doudna, supra note 9, at 568.
212. See Israel, supra note 101.
213. See Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2357 (2014).
214. See Israel, supra note 101.
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Instead, researchers must find a way to get the entire Cas9/gRNA
complex into the cell.215 However, this is incredibly difficult to do.216
When the Berkeley researchers announced that they had found a
way to use gold particles to transport a Cas9/gRNA complex into the
cells of mice suffering from muscular dystrophy, it was ground-
breaking news.217 Because (1) this technique was developed relative-
ly recently, (2) researchers have only published one paper describing
it,218 and (3) its efficacy has not been demonstrated for other treat-
ments, the delivery techniques for CRISPR-Cas9 anti-viral treat-
ments require an inventive concept that satisfies the second prong
of the Alice analysis.
Finally, the anti-viral uses of CRISPR-Cas9 systems are not
“directed to or encompassing a human organism”219 within the
meaning of the AIA. Neither the long-standing USPTO policy
against issuing patents encompassing human beings, nor the AIA,
have prevented patents from issuing on antiviral drugs.220 It is
important to note that a CRISPR-Cas9 treatment for a viral
infection is patentable only to the extent that it targets the virus’s
DNA, not the patient’s.221 The CRISPR-Cas9 anti-viral treatments
that have been proposed edit out specific portions of the viral DNA,
leaving the patient’s DNA unaltered and thus avoiding this
problem.222 Because CRISPR-Cas9 treatments do not alter the
human genome in any way,223 they are no different—with the
exception of their incredible effectiveness—than other anti-viral
215. Id.
216. See id.
217. See id.
218. At the time this Note was written. See id.
219. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
220. See, e.g., U.S. Patent No. 5,108,993 (issued Apr. 28, 1992) (a patent on a popular anti-
HIV drug not declared invalid under long-standing USPTO policy or the AIA).
221. See Kaminski et al., supra note 80, at 10 (“[W]e developed CRISPR/Cas9 techniques
that eradicated integrated copies of HIV-1 [DNA] from human ... cells, inhibited HIV-1 infec-
tion in ... human ... cells, and suppressed viral replication ex vivo in ... cells of HIV-1+
patients.”).
222. See id.
223. Id.
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drugs that have been granted patent protection.224 They should
therefore not be treated any differently on their patent applications.
2. Treating Bacterial Infections
Like the anti-viral applications of CRISPR-Cas9, the anti-
bacterial applications should also be granted patent protection. The
analysis here is largely similar to the anti-viral application
analysis.225 Although CRISPR-Cas9 systems naturally occur as an
immune response in bacteria, the response is geared towards fight-
ing viral infections, and is not directed against the bacteria itself.226
Therefore, anti-bacterial applications of CRISPR-Cas9 do not occur
in nature. The techniques for delivering anti-bacterial CRISPR-Cas9
treatments are also not widely used, because they were only
recently developed.227 Although some bacteria already contain Cas9
proteins that could be paired with an inserted gRNA, it is more
useful to insert an entire Cas9/gRNA complex, a technique that has
not yet been tested in humans.228 Finally, because the CRISPR-Cas9
treatments destroy bacterial DNA, and no human DNA,229 the
treatments do not run afoul of the AIA.230 Anti-bacterial applications
of CRISPR-Cas9 should therefore be patentable.
B. Where Patent Protection Will Not Apply
On the other hand, CRISPR-Cas9 therapies used to edit somatic
and germline cells should not be granted patent protection. While
these therapies satisfy both prongs of the Alice analysis because
they do not already occur in nature231 and do require an inventive
224. See, e.g., U.S. Patent No. 5,108,993 (issued Apr. 28, 1992) (a patent on a popular anti-
HIV drug not declared invalid under long-standing USPTO policy or the AIA).
225. See supra Part III.A.1.
226. See Sternberg & Doudna, supra note 9, at 568-69.
227. Israel, supra note 101.
228. See id. The Berkeley muscular dystrophy researchers did successfully use CRISPR-
Gold to insert complete Cas9/gRNA complexes into mice, and hope to begin human trials
shortly. See id.
229. Koo & Kim, supra note 8, at 40.
230. See supra Part II.B.
231. See infra notes 236-39, 252-54 and accompanying text.
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concept,232 they are “directed to or encompassing a human organ-
ism”233 in violation of the AIA.234
1. Editing Somatic Cells
Patent protection should not be granted to CRISPR-Cas9 systems
designed to edit somatic cells. These systems fail to clear the final
hurdle to patentability. While somatic cell editing of this kind does
not occur in nature and does use techniques that are wide-spread,
it is still not patentable because it is “directed to or encompassing
a human organism.”235
CRISPR-Cas9-mediated somatic cell editing does not occur in
nature under the Myriad standard (or, for that matter, under any
other rational standard).236 As discussed above in Part I.B.3,
CRISPR-Cas9 evolved as an immune response in bacteria and is
only present in bacteria. Although CRISPR-Cas9 does naturally
occur in bacteria, editing somatic cells in humans is not its natural
use.237 Inventors would have a stronger patent claim to this use
than the inventors in Myriad had to the cDNA.238 There, the
researchers were only removing certain portions of the naturally
occurring DNA.239 Here, inventors are completely altering what the
naturally-occurring phenomenon is used for.
Somatic-cell editing using CRISPR-Cas9 also does not employ
widely-used techniques, and thus requires an inventive leap that
satisfies the second prong of the Alice test.240 Because human cells
do not have Cas9 proteins already in them, researchers cannot
merely inject gRNA into cells that they want to edit and expect that
the edits will actually occur.241 Instead, researchers must find a way
to get the entire Cas9/gRNA complex into the cell.242 However, as
232. See infra notes 240-46, 254-56 and accompanying text.
233. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
234. See infra notes 240-43, 253-57 and accompanying text.
235. Leahy-Smith America Invents Act (AIA) § 33(a).
236. See supra Part I.B.3.
237. See Israel, supra note 101.
238. See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595 (2013).
239. Id.
240. See Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014).
241. See Koo & Kim, supra note 8, at 40.
242. See id.
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discussed above, this is incredibly difficult to do.243 The muscular
dystrophy researchers who discovered CRISPR-Gold just published
their discovery, and the technique has yet to be attempted in
humans.244 Because this technique was developed relatively recent-
ly, and because researchers have only published one paper describ-
ing it, the delivery techniques for CRISPR-Cas9 somatic cell editing
treatments are certainly not wide-spread, and require an inventive
concept to apply.245 Therefore, CRISPR-Cas9 treatments that edit
somatic cells clear both prongs of the Alice test.246
The stumbling block for researchers seeking to patent somatic
cell-editing CRISPR-Cas9 systems is the provision of the AIA that
dictates that no patent may be issued for a technology that is
“directed to or encompassing a human organism.”247 By their very
nature, CRISPR-Cas9 systems used to edit somatic cell DNA are
designed to alter a human organism.248 Indeed, the invention of
CRISPR-Gold as a delivery mechanism, which solves the problem of
how to efficiently deliver the Cas9/gRNA complex into somatic
cells,249 only complicates the AIA issue. Whereas before scientists
would have injected the Cas9/gRNA complex directly into the cells
they wished to affect, now they simply have to inject the solution
containing the Cas9/gRNA complexes into the body of the patient,
potentially impacting any cell containing the target DNA.250 An
invention that has the potential to fundamentally alter the DNA in
every cell in the body is clearly “directed to ... a human organism,”251
and should not receive patent protection under the AIA.
2. Editing Germline Cells
CRISPR-Cas9 systems designed to edit germline cells should also
not be granted patent protection. The analysis here is very similar
243. See Israel, supra note 101.
244. Id.
245. See id.
246. Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014).
247. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
248. Israel, supra note 101.
249. Id.
250. See id.
251. Leahy-Smith America Invents Act (AIA) § 33(a).
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to the somatic cell system analysis above: systems designed to edit
germline cells clear the first two hurdles to patentability, but
stumble upon the third. CRISPR-Cas9 does not naturally edit
germline cells in nature.252 It does not even naturally occur in
humans, and in the bacteria where it does naturally appear, it is
used solely for the purpose of destroying viral DNA.253 Germline
editing systems therefore exceed the Myriad standard.254 Germline
editing using CRISPR-Cas9 also does not use techniques that are
widely employed, and thus require an inventive concept.255 There is
(as of yet) no wide-spread genetic editing of any kind of human
germline cells.256
The argument is even stronger for CRISPR-Cas9-mediated edit-
ing of germline cells than it is for somatic cells that the technique
is “directed to or encompassing a human organism.”257 The benefit
of germline editing (from a research and treatment perspective) is
that if scientists can overcome issues with mosaicism, the altered
DNA will be expressed in every cell of the adult body.258 An inven-
tion designed to fundamentally alter the DNA in every cell in the
body is clearly “directed to ... a human organism.”259 The altered
DNA also has the potential to be passed on to the offspring of edited
individuals, ensuring that the offspring will have edited DNA fully
incorporated into their genome.260 Moreover, serious ethical
concerns will likely prevent the USPTO from issuing patents on any
technology that could so fundamentally alter a person’s genetic
code.261 For these reasons, CRISPR-Cas9 systems designed to edit
germline cells should also be unpatentable.
252. Sternberg & Doudna, supra note 9, at 568.
253. Id.
254. See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595 (2013).
255. See, e.g., Rana et al., supra note 13 (noting the only known CRISPR-Cas9 therapy
currently being used in humans is a treatment for cancer patients).
256. See Neergaard, supra note 14.
257. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
258. Koo & Kim, supra note 8, at 40.
259. Leahy-Smith America Invents Act (AIA) § 33(a).
260. Koo & Kim, supra note 8, at 40.
261. See Letter from James Rogan, Dir., U.S. Patent & Trademark Office, to Ted Stevens,
Chairman, Comm. on Appropriations, U.S. Senate, supra note 140.
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IV. COUNTERARGUMENTS
This Part addresses counterarguments to the normative frame-
work outlined in Part III. It considers and rejects arguments that
CRISPR-Cas9 should not be patentable at all;262 that patents have
been granted on some CRISPR-Cas9-based therapies, and therefore
all therapies should be patentable;263 and that certain somatic cell
editing should be patentable.264
A. CRISPR-Cas9 Should Not Be Patentable at All
As noted above, some scholars have argued that CRISPR-Cas9
should be considered unpatentable altogether.265 Benjamin Tuttle
believes that Myriad and Alice foreclose patentability for all
CRISPR-Cas9 systems, because they “share molecular and genetic
structure and function to the naturally-occurring molecules from
which they derive.”266 Tuttle argues that the systems thus fail the
first prong of the Alice test, and are subject to the second prong,
which he claims they also fail.267 Tuttle admits that CRISPR-Cas9
systems used to modify non-bacterial DNA may qualify as an
“inventive concept,” but argues that policy considerations should
outweigh the value of protecting the invention.268 In the context of
the subset of CRISPR-Cas9 systems that could be used as thera-
pies for human illness, Deborah Ku may actually support Tuttle.269
She writes that patent protection applies when “the claimed
CRISPR system is not used as an immune system, but as a genome
editing tool. Hence its function is different [than it would be in
nature].”270
Tuttle’s paper was written in the context of the patent dispute
between The Broad Institute and the University of California, and
262. Infra Part IV.A.
263. Infra Part IV.B.
264. Infra Part IV.C.
265. Tuttle, supra note 180, at 392; supra notes 181-83 and accompanying text.
266. Tuttle, supra note 180, at 404.
267. Id. at 404-05.
268. Id. at 405.
269. See Ku, supra note 180, at 435.
270. Id.
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does not directly deal with therapeutic applications of CRISPR-
Cas9.271 Taken in the context of therapeutic applications, however,
his arguments about the patentability of CRISPR-Cas9 carry
significantly less weight. His arguments fail to account for the
magnitude of the inventive leap when a genetic system used as part
of an immune response in bacteria is repurposed as a medical
treatment in humans.272
As Ku wrote in her paper, even assuming that CRISPR-Cas9
systems fail the first prong of the Alice test, they do not fail the
second.273 The human intervention required to transform a bacteri-
al immune response into a genetic-editing technology that can be
used in human cells is an inventive leap large enough to satisfy the
second prong of the Alice test.274 This is a massive step forward that
reflects the culmination of the policy goals that Tuttle expresses,275
and far outweighs any reasons not to grant patent protection to
CRISPR-Cas9 therapies in some instances.
B. Patents Have Issued on Some CRISPR-Cas9-Based Therapies
In contrast, those arguing in favor of granting patents on all
CRISPR-Cas9-based therapies might observe that patents already
have issued on CRISPR-Cas9 systems used to edit human immune
cells,276 and patents should therefore be issued on all CRISPR-
based therapies. However, this position fails to account for the fact
that while patents are given a presumption of validity,277 “the
ultimate question of patent validity is one of law,” to be determined
by a court.278 Until a court has determined the validity of these
271. Id. at 436; Tuttle, supra note 180, at 404-05.
272. See Koo & Kim, supra note 8, at 40.
273. Ku, supra note 180, at 437.
274. Id.; Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014).
275. Tuttle, supra note 180, at 405.
276. Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells, BUS. WIRE
(Feb. 13, 2018, 12:01 AM), https://www.businesswire.com/news/home/20180212006461/en/
Issued-U.S.-Patents-Granted-Cellectis-CRISPR-T-Cells [https://perma.cc/DFA9-L759]
(describing patents that issued on CRISPR-Cas9-based technologies used to edit human T-
cells).
277. 35 U.S.C. § 282(a) (2012).
278. Microsoft Corp. v. i4i P’ship, 564 U.S. 91, 96 (2011) (quoting Graham v. John Deere
Co., 383 U.S. 1, 17 (1966)).
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patents, there is no reason to believe that patents on CRISPR-Cas9
therapies are per se valid.
C. Some Somatic Cell Editing Should Be Patentable
In a similar vein, CRISPR-Cas9 therapies that edit certain somat-
ic cells arguably should be patentable. For example, CRISPR-Cas9
therapies could be used to knock out the genes that cause unre-
stricted growth in tumor cells.279 Such unrestricted growth is not
normally present in the human genome,280—the argument goes—so
destroying the genes that cause it using CRISPR-Cas9 is a treat-
ment that is not “directed to or encompassing a human organism.”281
What this argument fails to account for is that tumor cells are
created when human DNA is mutated so that the factors that nor-
mally restrict cell growth are no longer active.282 The cancer cells
still have human DNA, and even if that particular expression of
DNA is not the default in humans, it does still naturally occur in
them.283 Any attempt to edit out the mutation is thus an attempt to
edit human DNA in a live patient, and is therefore “directed to ... a
human organism.”284
CONCLUSION
In his short story, Boyle paints a dark and concerning picture of
a CRISPR-mediated future, made all the more worrisome because,
as discussed above,285 many of the steps that he describes have
already been taken:
When the CRISPR technology first came to light, governments
and scientists everywhere assured the public that it would be
279. See Ingrid Lobo, Chromosome Abnormalities and Cancer Cytogenetics, NATURE
EDUC. (2008), https://www.nature.com/scitable/topicpage/chromosome-abnormalities-and-
cancer-cytogenetics-879 [https://perma.cc/4VBC-CPQB].
280. Id.
281. Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340
(2011).
282. Lobo, supra note 279.
283. Id.
284. Leahy-Smith America Invents Act (AIA) § 33(a).
285. See supra Part I.B.
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employed only selectively, to fight disease and to rectify congeni-
tal deformities, editing out the mutated BRCA1 gene that
predisposes women to breast cancer, for instance, or eliminating
the ability of the Anopheles mosquito to carry the parasite that
transmits malaria. Who could argue with that? Genome-editing
kits (“Knock Out Any Gene!”) were sold to home hobbyists, who
could create their own anomalous forms of yeast and bacteria in
their kitchens, and it was revolutionary—and, beyond that, fun.
Fun to tinker. Fun to create.... The Chinese were the first to
renounce any sort of regulatory control and upgrade the human
genome, and, as if they weren’t brilliant enough already, they
became still more brilliant as the first edited children began to
appear, and of course we had to keep up.286
Fortunately, safeguards in intellectual property laws will likely
mean that CRISPR-Cas9 therapies are only patentable under the
Myriad standard and the AIA when they do not lead to upgrading
the human genome.287 DNA in somatic or germline cells is incorpo-
rated into the body, and, in the case of the germline cells (or an or-
gan donor who gives an organ containing DNA edited by CRISPR),
could even be passed on to another person.288 CRISPR-Cas9 systems
in somatic or germline cells should not be patentable under the AIA,
because they are “directed to ... a human organism.”289
However, CRISPR-centered treatments for viral and bacterial
infections should be patentable.290 Like pharmaceuticals, they
should not lose their patent protection simply because they entered
the human body.291 Because they do not occur in nature and
represent an inventive leap, antiviral and antibacterial CRISPR-
Cas9 treatments satisfy the Myriad and Alice standards.292 Like-
wise, the genetic editing techniques used to treat viral and bacterial
infections will not run afoul of the AIA, because, like current
pharmaceuticals, they are directed at foreign organisms that inhabit
humans, and not the “human organism” itself.293 This is no small
286. Boyle, supra note 1.
287. See supra Part III.A.
288. See supra Parts I.B.3, I.B.4.
289. Leahy-Smith America Invents Act (AIA) § 33(a); see also supra Part III.B.
290. See supra Part III.A.
291. See supra Part II.A.
292. See supra Part III.A.
293. See supra Part II.
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step forward. Currently, there are no cures for viral infections,
including those that are highly lethal (such as HIV/AIDs), and those
that are incredibly common (the flu).294 Additionally, the rapid
evolution of bacteria means that antibiotic-resistant strands of
highly dangerous illnesses like tuberculosis will soon be entirely
unsusceptible to traditionally effective antibiotics, requiring a new
kind of treatment entirely.295
The patent system as it exists now will help to ensure that some
of the therapeutic applications of CRISPR-Cas9 receive protection,
while others, too clearly “directed to ... a human organism” will re-
main unprotected.296 This outcome should help prevent some of the
ethical concerns that Boyle highlights about CRISPR-Cas9 thera-
pies from becoming a reality.297
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